MMWR Morb Mortal Wkly Rep. 2013 Jun 7;62(22):443-7.
In 2005, the World Health Organization (WHO) Regional Committee for the Western Pacific Region (WPR) resolved that WPR should aim to eliminate measles by 2012. The recommended measles elimination strategies in WPR include 1) achieving and maintaining high (≥95%) coverage with 2 doses of measles-containing vaccine (MCV) through routine immunization services and by implementing supplementary immunization activities (SIAs), when required; 2) conducting high-quality, case-based measles surveillance; 3) ensuring high-quality laboratory surveillance, with timely and accurate testing of specimens to confirm or discard suspected cases and detect measles virus for genotyping and molecular analysis; and 4) establishing and maintaining measles outbreak preparedness for rapid response and ensuring appropriate case management. This report updates the previous report and describes progress toward eliminating measles in WPR during 2009-2012. During this period, measles incidence reached a historic low, decreasing by 83%, from 34.0 to 5.9 cases per million population. However, to achieve measles elimination in WPR, additional efforts are needed to strengthen routine immunization services in countries and areas with <95% coverage with the routine first (MCV1) or second dose of MCV (MCV2), to introduce a MCV2 dose in the four remaining countries and areas that do not yet have a routine 2-dose MCV schedule, and to use SIAs to close immunity gaps among measles-susceptible populations in countries and areas that have ongoing measles virus transmission.
2005 年,世界卫生组织(世卫组织)西太平洋区域委员会(西太区)决定,西太区力争到 2012 年消除麻疹。西太区推荐的消除麻疹策略包括:1)通过常规免疫服务和实施补充免疫活动(SIAs),实现并保持高水平(≥95%)的两剂含麻疹成分疫苗(MCV)覆盖率,在有需要时开展;2)开展高质量、基于病例的麻疹监测;3)确保高质量实验室监测,及时准确地检测标本,以确认或排除疑似病例,并检测麻疹病毒进行基因分型和分子分析;4)建立和维持麻疹疫情防范措施,以便快速应对,并确保适当的病例管理。本报告更新了以往的报告,介绍了 2009-2012 年期间西太区消除麻疹的进展情况。在此期间,麻疹发病率达到历史最低水平,下降了 83%,从每百万人口 34.0 例降至 5.9 例。然而,要在西太区实现消除麻疹,还需要作出更多努力,加强常规免疫服务,在覆盖率低于 95%的国家和地区提高常规首剂(MCV1)或第二剂 MCV(MCV2)的接种率,在其余四个尚未实行常规两剂 MCV 免疫程序的国家和地区引入一剂 MCV2,利用 SIAs 消除在有麻疹病毒传播的国家和地区麻疹易感人群中的免疫空白。